News

Under the terms of the licensing agreement, Ortho-Clinical Diagnostics and Novartis Vaccines and Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for hepatitis

AV-412 produced potent anti-tumor effects in several variants of EGFR kinase, including L858R and T790M double mutants, which are known to be resistant to erlotinib (Tarceva) and gefitinib

The multi-national Phase IIa trial of ARC1779 is expected to enroll approximately 300 patients. The trial is a dose-ranging, randomized, double-blind study using ReoPro as a comparator. The

The Fast Track designation allows for frequent communications with the FDA and the possibility of submitting portions of the marketing application (a BLA) before the complete BLA is

The goal of this open-label, multi-center study is to determine the anti-tumor activity of IPI-504 in patients with hormone-refractory prostate cancer (HRPC), also referred to as castration-resistant prostate

The study is designed to evaluate efficacy of PH-10 in a total of 25 subjects with moderate to severe forms of the disease and will be conducted at

Under the terms of the agreement, Acambis will continue to perform development activities, up to and including the filing of a license application in the US. Acambis will

NV-52 is thought to work as a selective thromboxane synthase (TXS) inhibitor, which researchers believe may play a major therapeutic role in inflammatory bowel disease (IBD) due to

The Alphagenics human papillomaviruses (HPV) test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories. Alphagenics Diaco’s HPV DNA